In-Process Quality Control for Pharmaceutical Glass Vials

Introduction: The Critical Role of In-Process Quality Control in Glass Vial Manufacturing

Pharmaceutical glass vials are not merely containers—they are integral components of the drug product’s container closure system, directly impacting patient safety, drug stability, and product efficacy. The manufacturing of these vials demands exceptional precision, as even minor dimensional deviations or surface defects can compromise container closure integrity, lead to drug product recalls, or, in the worst case, endanger patient lives.

In-process quality control (IPQC) is the systematic monitoring and inspection of glass vials during the manufacturing process. Unlike end-product testing, which only verifies final quality, in-process controls provide real-time feedback that enables immediate corrective action, reduces waste, and ensures consistent product quality. For pharmaceutical glass vials—whether tubular (ISO 8362-1) or molded (ISO 8362-4)—a robust IPQC program is not optional; it is a regulatory expectation under cGMP and a fundamental requirement for patient safety.

At Vialab Pharmaceutical Packaging Co., Ltd. , we understand that the quality of the glass vial directly impacts the performance of the complete container closure system. Our aluminum caps and aluminum-plastic combination caps are designed to work with vials manufactured to the highest quality standards. This article provides a comprehensive examination of in-process quality control for pharmaceutical glass vials—covering the key control points, inspection methodologies, regulatory standards, and best practices that ensure consistent, reliable vial quality.

1. The Regulatory Framework for Glass Vial Quality

1.1 USP <660> Containers – Glass

USP <660> establishes the foundational requirements for glass containers intended to come into direct contact with pharmaceutical products. Glass containers meeting Type I performance are suitable for most products for parenteral and nonparenteral uses (e.g., borosilicate). Type II performance containers are suitable for most acidic and neutral aqueous products, while Type III performance containers (e.g., soda-lime silica) are usually not used for parenteral products except where suitable stability data indicate they are satisfactory.

The 2023 revision of USP <660> introduced significant changes:

New glass materials: Aluminosilicate glass and quartz glass have been added
Removal of the Glass Grains Test: Replaced with Wavelength Dispersive X-Ray Fluorescence (WDXRF) for elemental composition identification
Elimination of the Surface Etching Test: Streamlining the testing process
New extractable arsenic test: Using inductively coupled plasma (ICP) technology
Revised Spectral Transmission Test: For colored glass containers

The shift from a composition-based to a performance-based classification system means that “a glass of any composition that is able to pass the current Type I performance based hydrolytic resistance tests should be able to be classified as Type I glass”. This change, made at the request of the FDA to address glass vial shortages, gives manufacturers greater flexibility while reinforcing the need to independently characterize glass composition.

1.2 USP <1660> Evaluation of the Inner Surface Durability of Glass Containers

USP <1660> provides comprehensive guidelines on the formation, processing, and testing of glass containers used in pharmaceutical packaging. It covers various glass types, including aluminosilicate, borosilicate, quartz, and soda-lime-silica glass.

The chapter was developed in response to product recalls that increased the pharmaceutical industry’s awareness of glass quality and glass delamination—the formation of glass flakes in a vial. USP <1660> recommends approaches to predict the potential formation of glass particles and delamination and to detect their occurrence. It emphasizes the importance of collaboration between pharmaceutical manufacturers and glass vendors to maintain high-quality standards throughout the glass supply chain.

1.3 ISO 8362 Series

The ISO 8362 series specifies the form, dimensions, and capacities of glass vials for injectable preparations. ISO 8362-1 covers injection vials made of glass tubing, while ISO 8362-4 covers molded glass vials. These standards specify not only dimensions but also the material from which containers shall be made and the performance requirements of those containers.

1.4 FDA Guidance and cGMP Requirements

Under cGMP and Acceptable Quality Level (AQL) controls, every tubular glass vial must undergo 100% visual camera inspection. The FDA recommends applicants use risk management principles described in ICH Q9(R1) Quality Risk Management and tools described in ICH Q12 for pharmaceutical product lifecycle management.

2. The Glass Vial Manufacturing Process: Key Quality Control Points

2.1 Raw Material Control

The foundation of glass vial quality begins with raw materials. Glass composition is weighed, blended, and introduced into the furnace. Pharmaceutical glass manufacturers produce the three types of glass described in the pharmacopoeia: Type I borosilicate glass (neutral in the mass), Type II soda-lime glass with high hydrolytic surface resistance, and Type III soda-lime glass with low hydrolytic resistance.

The glass composition and the container manufacturing process define which elements can leach into the drug product, and to what extent, over time as a result of drug-container interaction. Incoming raw material testing must verify:

Chemical composition meeting pharmacopoeial requirements
Freedom from contaminants
Consistency across batches

2.2 Melting and Forming

Specially designed furnaces reach temperatures of up to 1600°C (2900°F), with raw materials converted to molten glass over a 24-hour period. For molded vials, gobs are formed, cut, and delivered into the blank mold, with vials formed using a press-and-blow process or blow-and-blow process. Fully automated IS forming machines are equipped with multiple stations to form from 4 up to 48 vials per cycle.

For tubular glass vials, glass tubes are heated, shaped, and cut to give the dimensional parameters in three main steps: shoulders and neck forming (including 100% on-line dimensional inspection), followed by vials being individually picked and placed on the conveyor belt of the annealing lehr.

Key in-process controls during forming:

Temperature monitoring: Using infrared pyrometers for total quality control
Dimensional inspection: Performed on the forming machine when the container is still mounted in a chuck
Wall thickness measurement: Ensuring uniform glass distribution

2.3 Annealing

Annealing is a critical process step that relieves internal stresses in the glass. Newly formed vials undergo controlled cooling in annealing ovens to eliminate internal stresses, preventing microfractures and enhancing mechanical stability. The process involves forming at high temperatures (1200°C–1400°C) followed by inline annealing at approximately 560°C.

Annealing quality verification:

The injection vials shall be annealed so that the maximum residual stress does not produce an optical retardation exceeding 40 nm per millimetre of glass thickness, when the vials are viewed in a strain viewer
Polarized light inspection detects residual stress patterns
Inadequate annealing can lead to vial breakage during filling, sterilization, or transportation

3. Dimensional Inspection: Precision at Every Stage

3.1 The Importance of Dimensional Control

Glass pharmaceutical primary packaging must be produced under very tight tolerances. Dimensions must be 100% inspected to guarantee the full functionality of the packaging. Dimensional control is critical because:

Vials must fit precisely in filling equipment
Neck finish dimensions must match closure specifications
Consistent dimensions ensure reliable crimping and sealing
Dimensional deviations can compromise container closure integrity

3.2 Key Dimensional Parameters

ISO 8362-1 specifies critical dimensional parameters for tubular glass vials including:

Outside diameter of the vial body (d₁)
Diameter of the neck finish (d₂)—the critical dimension for closure compatibility
Inside diameter of the neck opening (d₃)
Total height of the vial (h₁)
Height of the neck finish (h₂)
Height of the stopper seating area (h₃)

Typical dimensional tolerances include outside diameter deviations of ±0.05 mm, height tolerances of ±0.1 mm, and wall thickness uniformity of ≤0.02 mm.

3.3 In-Line Dimensional Inspection Systems

Modern glass vial manufacturing employs advanced in-line inspection systems:

Dimensional inspection on the forming machine: Performed when the container is still mounted in a chuck, allowing immediate detection and correction of deviations.

Inspection before the annealing oven: On the after-forming line, to measure inner diameter and length.

100% camera inspection: Under cGMP and AQL controls, every tubular glass vial undergoes 100% visual camera inspection, assuring delivery of vials that are dimensionally accurate and free of physical and cosmetic defects.

Statistical Process Control (SPC): Dimensions are measured with SPC, giving the machine operator instant data in an overview format. SPC enables:

Real-time process monitoring
Early detection of trends toward out-of-specification conditions
Data-driven process adjustments
Demonstration of process capability (Cpk)

3.4 Bottom and Neck Inspection

The bottom of the container plays a fundamental part for the integrity of the container during the filling process. In-line measurement systems allow for micrometric precision measurement of:

Bottom thickness
Bottom concavity
Footprint

Neck inspection is equally critical, as neck finish defects can compromise closure integrity. High-risk cracks, though less frequent, are particularly dangerous because they are difficult to detect.

4. Visual and Cosmetic Inspection

4.1 The Critical Nature of Visual Inspection

Visual inspection is nowadays mandatory equipment in a state-of-the-art tube converting production line. Even the smallest surface defects can compromise the integrity of sterile drugs.

Every packaging component must undergo 100% visual inspection to identify defects such as cracks, chips, or bubbles in glass vials. The optical inspection of pharmaceutical glass packaging is considered a critical step in quality control.

4.2 Types of Cosmetic Defects

Advanced camera-based inspection systems detect cosmetic defects along the entire surface of the vials—body, shoulder, neck, collar, flange surface, and bottom side—including:

Cracks: Structural defects that can lead to vial failure
Scratches: Surface abrasions that may weaken the glass
Airlines: Internal glass defects that can affect optical clarity and structural integrity
Bubbles: Air pockets in the glass that can compromise strength
Dirt marks: Surface contamination
Chips: Missing glass material
Strain: Internal stress patterns visible under polarized light

4.3 Automated Visual Inspection Technology

Optical surface inspection devices control online and without contact 100% of the products for cosmetic defects as small as 50 microns. These systems can detect and eject defects such as dirt, scratches, chips, air-lines, loose glass particles, and cracks.

Proprietary visual inspection systems feature:

Inspection of all areas of the vial: finish/neck, shoulder, body, hyper-bottom
Custom software capable of defect recognition and classification
Adjustable sensitivity based on client requirements

High-technology inspection systems ensure both cosmetic and dimensional quality, with tighter AQLs leading to reduced vial-to-vial and vial-to-metal contact, resulting in no visible defects, scratches, or contamination.

4.4 PDA Technical Report No. 43

PDA Technical Report No. 43 provides detailed lexicons that visually illustrate glass nonconformities—one for molded glass bottles and vials, and four for tubular glass vials, ampoules, cartridges, and syringes. These standardized defect classifications enable consistent communication between suppliers and pharmaceutical manufacturers.

5. Container Closure Integrity and Compatibility Testing

5.1 The Role of Glass Vials in Container Closure Integrity

Container closure integrity (CCI) is vital to ensuring the sterility and safety of parenteral pharmaceuticals. The container closure system includes all packaging components that, when securely sealed, protect a drug product from contamination and degradation while maintaining its efficacy and safety throughout its shelf life.

Glass vials with rubber stoppers and aluminum overseals are the most common container-closure system for parenteral products. The vial’s dimensional accuracy directly impacts the ability to achieve and maintain CCI.

5.2 USP <1207> Package Integrity Evaluation

USP <1207> is regarded as the most thorough guidance to date on CCI concepts for sterile and critical products such as vials and syringes. Deterministic methods enable quantitative detection, providing objective and reliable results.

A deterministic leak test method having the ability to detect leaks at the product’s maximum allowable leakage limit is required. Common deterministic leak test methods include:

Vacuum decay testing (ASTM F2338)
Helium leak detection
High voltage leak detection
Laser-based headspace analysis

5.3 Compatibility Testing

The compatibility of glass vials with closures (stoppers and aluminum caps) must be verified through comprehensive testing. Vials can be converted from glass tubes (tubular vials) or formed by a press and blow process from a glass gob (molded vial).

Compatibility testing must consider:

Dimensional fit between vial neck finish and closure
Crimping performance
Seal integrity after sterilization
Long-term stability under ICH conditions

6. Glass Delamination: Prevention Through Quality Control

6.1 Understanding Glass Delamination

Glass delamination, which ultimately results in the appearance of lamellae (glass flakes), is a serious quality issue and can result in a product recall. Delamination is a lagging indicator of structural instability—it represents the final stage of a seriously weakened glass surface structure and can be observed only at a point where prevention is no longer an option.

The issue of delamination is serious as it can cause glass particles to appear in vials, a problem that has forced a number of drug product manufacturers to recall products. In 2010, glass flakes were discovered in nine different drug products due to glass delamination, leading to immediate recalls.

6.2 Predictive Screening

USP <1660> recommends approaches to monitor “early stage” indicators through predictive screening studies which begin with an assessment of the glass materials. Tests for delamination combine an examination of the vial surface and analysis of an aggressive test solution to predict the propensity of the internal glass surface of vials to delaminate.

Indicators of potential delamination include:

Appearance of a pitted, fractured surface instead of a smooth surface
Increases in SiO₂ concentration in test solution
Increases in the ratio of SiO₂/B₂O₃ or Si/Al
Increases in the number of subvisible particulates in the solution
A fall in pH

6.3 Manufacturing Controls to Prevent Delamination

Preventing delamination requires controls throughout the manufacturing process:

Glass composition: Selecting glasses with appropriate chemical durability
Forming process control: Avoiding conditions that weaken the inner surface
Surface treatment: Appropriate treatment to enhance durability
Annealing: Proper stress relief to prevent structural weakness

Mechanical energy from shaking or vial-to-vial contact may dislodge lamellae from the weakened internal surface, making handling controls equally important.

7. Cleanroom Inspection and Packaging

7.1 Cleanroom Inspection

Once formed and cooled, 100% of the vials and bottles are inspected in a cleanroom environment to control:

Dimensions, including wall thickness and diameters
Glass integrity
Seal and bottle integrity
Neck and bottom inspection
Defects such as chipped glass, blister, distortion, and finish distortion affecting tightness

7.2 Particle Control

Before packing, all vials and bottles are turned upside down and blown in the cleanroom to minimize the risk of loose particles. Shrink-wrap packs are formed inside the cleanroom for maximum cleanliness, and automated palletization offers consistency and avoids human manipulation with the vials.

7.3 Batch Release

Batch release is based on manufacturing track records and QC results. Each label contains data critical for complete traceability, and compliance certificates are systematically issued with each delivery.

8. Statistical Process Control and Continuous Improvement

8.1 The Role of SPC in Glass Vial Manufacturing

Statistical Process Control (SPC) is essential for maintaining consistent quality in glass vial manufacturing. SPC enables:

Real-time monitoring of critical process parameters
Early detection of process deviations
Data-driven corrective actions
Demonstration of process capability

8.2 Process Capability (Cpk)

Capability Index (Cpk) is a statistical measure of process capability demonstrating the ability of a process to produce output within specification limits. A Cpk value above 1.33 is generally considered acceptable, while values above 1.67 indicate excellent process capability.

8.3 Continuous Improvement

Forming tools are designed to reduce glass container tolerances and to maintain their precision for long forming runs. The converting process can be controlled to reduce effects on the chemical properties of the glass. Continuous improvement initiatives should focus on:

Reducing dimensional variability
Minimizing cosmetic defects
Enhancing process efficiency
Improving first-pass yield

9. Vialab’s Commitment to Quality

At Vialab Pharmaceutical Packaging Co., Ltd. , we recognize that the quality of the glass vial is foundational to the performance of the complete container closure system. While our core products are aluminum caps and aluminum-plastic combination caps, we understand that these components must work in perfect harmony with high-quality glass vials to ensure container closure integrity.

Our commitment to quality encompasses:

Dimensional precision: Our caps are manufactured to tolerances that ensure proper fitment with ISO 8362-compliant glass vial neck finishes
Compatibility validation: We work with our partners to ensure that our caps are compatible with their chosen vial and stopper systems
Comprehensive documentation: We provide full traceability of our products, supporting our partners’ quality control and regulatory compliance efforts
Regulatory expertise: We stay current with evolving USP standards, including USP <660>, USP <1660>, and the transition to performance-based glass classification

Whether you require 13 mm, 20 mm, or 32 mm aluminum caps or aluminum-plastic combination caps, Vialab delivers components designed to work seamlessly with pharmaceutical-grade glass vials manufactured to the highest quality standards.

Conclusion

In-process quality control for pharmaceutical glass vials is a comprehensive, multi-stage process that ensures the safety, efficacy, and reliability of parenteral drug products. From raw material selection through melting, forming, annealing, dimensional inspection, visual inspection, and cleanroom packaging, every stage of the manufacturing process requires rigorous control and monitoring.

The regulatory framework—including USP <660>, USP <1660>, ISO 8362, and FDA guidance—provides clear expectations for glass vial quality. The shift to performance-based glass classification under USP <660> offers manufacturers greater flexibility while reinforcing the need for thorough characterization and testing.

Advanced inspection technologies—including 100% camera-based dimensional and cosmetic inspection, SPC, and predictive screening for delamination—enable manufacturers to detect and correct defects in real time, ensuring that only vials meeting the highest quality standards reach pharmaceutical fill-finish operations.

As the pharmaceutical industry continues to advance with new biologics, sensitive formulations, and complex delivery systems, the importance of robust in-process quality control for glass vials will only grow. At Vialab, we remain committed to supporting our partners with high-quality packaging components and the technical expertise needed to navigate the evolving quality and regulatory landscape.

References

USP <660> – Containers – Glass
USP <1660> – Evaluation of the Inner Surface Durability of Glass Containers
USP <1207> – Package Integrity Evaluation — Sterile Products
ISO 8362-1 – Injection containers and accessories — Part 1: Injection vials made of glass tubing
ISO 8362-4 – Injection containers and accessories — Part 4: Injection vials made of moulded glass
21 CFR Part 211 – Current Good Manufacturing Practice for Finished Pharmaceuticals
FDA Guidance for Industry: Container Closure Systems for Packaging Human Drugs and Biologics
ICH Q9(R1) – Quality Risk Management
ICH Q12 – Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management
PDA Technical Report No. 43 (Revised 2023) – Identification and Classification of Nonconformities in Moulded and Tubular Glass Containers for Pharmaceutical Manufacturing
Bartl K. Total quality in tubing glass manufacturing. J Parenter Sci Technol. 1993;47(2):93-7
Pharmaceutical Glass Vial Manufacturing Processes (Industry Standards)

This article is provided for informational purposes only and does not constitute regulatory advice. Manufacturers should consult with qualified experts and regulatory authorities for specific product validation and compliance.